Presented at the 7th Annual RAS-Targeted Drug Development Summit in Boston on September 17th, 2025.
Read More
Presented at the 7th Annual RAS-Targeted Drug Development Summit in Boston on September 17th, 2025.
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer
Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans